Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $60.00

Dyne Therapeutics (NASDAQ:DYN) had its target price hoisted by HC Wainwright from $46.00 to $60.00 in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ FY2027 earnings at ($1.65) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $1.56 EPS.

Other research analysts have also issued reports about the stock. Raymond James Financial upgraded shares of Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $31.00 to $35.00 in a research note on Monday, August 25th. Oppenheimer cut their price objective on shares of Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating on the stock in a report on Wednesday, November 12th. Lifesci Capital upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Sanford C. Bernstein restated a “market perform” rating and issued a $21.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, November 25th. Finally, Royal Bank Of Canada raised their price objective on Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Buy” and a consensus target price of $38.41.

Dyne Therapeutics Trading Up 6.8%

DYN opened at $19.69 on Monday. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $28.96. The stock has a market cap of $2.81 billion, a PE ratio of -5.38 and a beta of 1.30. The business has a 50 day moving average of $18.91 and a 200-day moving average of $14.18.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.05. Equities research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors have recently modified their holdings of DYN. CWM LLC increased its holdings in Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after buying an additional 1,900 shares in the last quarter. Chung Wu Investment Group LLC purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at about $30,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after acquiring an additional 2,446 shares during the last quarter. Quarry LP bought a new stake in shares of Dyne Therapeutics in the first quarter worth approximately $47,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.